23-GU-82-SI-PMC (SGN22E-004): A Study Of Intravesical Enfortumab Vedotin For Treatment Of Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Grants and Contracts Details

StatusActive
Effective start/end date4/22/244/22/26

Funding

  • Seagen Incorporated: $2.00